ESMO Asia Congress 2022

Abstract 350P

Background

Targeted therapy and immunotherapy opens a new era in the treatment of lung cancer. However, for the majority of patients who do not harbor certain molecular alterations, chemotherapy still plays a critical role in the treatment strategy. Neutropenia is a major dose-limiting toxicity of myelosuppressive chemotherapy and has been commonly found in lung cancer patients treated with platinum-based chemotherapy. Mecapegfilgrastim (code name HHPG-19K), a long-acting PEGrhG-CSF and a biosimilar to pegfilgrastim. Our study prospectively assessed effects of Mecapegfilgrastim in primary prevention of Chemotherapy-Induced Neutropenia in Patients With Advanced Lung Cancer in real world clinical practice.

Methods

Our study enrolled 25 patients who received chemotherapy alone or combined treatment protocols with high risk of febrile neutropenia (FN)＞20%, and prophylatically injected mecapegfilgrastim 6-mg fixed dose in cycle 1. All patients received 6 chemotherapy cycles every 21 days. The primary endpoint was the incidence of grade 3 neutropenia in cycle 1.

Results

This study included 25 patients from October 2021 to January 2022. 64% of the participants were Non-small Cell Lung Cancer(NSCLC) and 36% were Small Cell Lung Cancer(SCLC). The mean age of all the patients was 60 years. There was no incidence of grade ≥3 neutropenia in cycle 1, and well met the primary endpoint, there was even no incidence of grade ≥1 neutropenia in cycle 1. Fatigue (16%) was the most frequently reported adverse event (AE) possibly related to the study drug. No unexpected AEs were reported.

Conclusions

Prophylactic administration of mecapegfilgrastim could prevent the incidence of grade ≥3 neutropenia in cycle 1. and no unexpected AEs were observed in this study.